Geographically 31% of our sales in the third quarter were in US compared to 39% last year, with 69% of our sales outside of the US compared to 61% last year. This change is primarily driven by our April 1st acquisition of Laprolan. We were generally pleased with our performance, both domestically and abroad. Total sales for the first nine months of year increased 24% to reach $38.1 million from $30.3 million in same period of last year.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Rochester Medical Corporation Stock Upgraded (ROCM)

Rochester Medical Corporation's CEO Discusses Q3 2012 Results - Earnings Call Transcript

Rochester Medical Corporation's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Rochester Medical Corporation Stock Upgraded (ROCM)

Rochester Medical CEO Discusses F1Q2012 Results - Earnings Call Transcript